AU4542993A - Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine - Google Patents

Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Info

Publication number
AU4542993A
AU4542993A AU45429/93A AU4542993A AU4542993A AU 4542993 A AU4542993 A AU 4542993A AU 45429/93 A AU45429/93 A AU 45429/93A AU 4542993 A AU4542993 A AU 4542993A AU 4542993 A AU4542993 A AU 4542993A
Authority
AU
Australia
Prior art keywords
sibutramine
amount
pharmaceutically acceptable
human
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU45429/93A
Other languages
English (en)
Inventor
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU4542993A publication Critical patent/AU4542993A/en
Priority to AU48297/97A priority Critical patent/AU696392B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU45429/93A 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine Abandoned AU4542993A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48297/97A AU696392B2 (en) 1992-06-23 1997-12-11 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90303492A 1992-06-23 1992-06-23
US903034 1992-06-23
PCT/US1993/005967 WO1994000047A1 (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU48297/97A Division AU696392B2 (en) 1992-06-23 1997-12-11 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Publications (1)

Publication Number Publication Date
AU4542993A true AU4542993A (en) 1994-01-24

Family

ID=25416828

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45429/93A Abandoned AU4542993A (en) 1992-06-23 1993-06-22 Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine

Country Status (5)

Country Link
EP (1) EP0708639A4 (de)
JP (1) JPH07508281A (de)
AU (1) AU4542993A (de)
CA (1) CA2139000A1 (de)
WO (1) WO1994000047A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19518988A1 (de) * 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
GB9619962D0 (en) * 1996-09-25 1996-11-13 Knoll Ag Medical treatment
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
MXPA01009461A (es) * 1999-03-19 2004-03-19 Abbott Gmbh & Co Kg Tratamiento de osteoartritis.
CA2368083A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US20020115727A1 (en) * 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
DK1360169T3 (da) 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008993A1 (de) * 1980-03-08 1981-10-01 Röhm Pharma GmbH, 6100 Darmstadt Pharmazeutische zubereitungen
GB2098601B (en) * 1981-04-02 1985-07-24 Sandoz Products Ltd Improvements in or relating to organic compounds
ZA821577B (en) * 1981-04-06 1983-03-30 Boots Co Plc Therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤

Also Published As

Publication number Publication date
EP0708639A4 (de) 1997-08-20
EP0708639A1 (de) 1996-05-01
CA2139000A1 (en) 1994-01-06
WO1994000047A1 (en) 1994-01-06
JPH07508281A (ja) 1995-09-14

Similar Documents

Publication Publication Date Title
AU4542893A (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US6110973A (en) Methods for treating obesity and weight gain using optically pure (-)-bupropion
AU4542993A (en) Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
US5648396A (en) Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
RU2001614C1 (ru) R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
JP2003501344A (ja) （＋）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
WO2002060427A2 (en) Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
EP0687472A2 (de) Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
CZ20013607A3 (cs) Farmaceutický prostředek
MX2008000250A (es) Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
US4690949A (en) Therapeutic drug for dementia
CA2318960A1 (en) Pharmaceutical uses of optically pure (+)-bupropion
EP2277850A1 (de) 1-Amino-Alkylcyclohexane als 5-HT3- und neuronale-nicotinerge Rezeptorantagonisten
US20020006963A1 (en) Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds
AU721924B2 (en) Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5492933A (en) Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
US4141993A (en) Compounds of diphenylcyclopentylamine type and methods for their preparation
WO1995010270A1 (en) Method for treating urinary incontinence using optically pure s-terodiline